{"id":1643,"date":"2018-10-04T22:58:39","date_gmt":"2018-10-04T21:58:39","guid":{"rendered":"https:\/\/tris.sambrownprojects.com\/deerfield-provides-125-million-debt-financing-to-tris-pharma\/"},"modified":"2023-08-23T15:26:58","modified_gmt":"2023-08-23T14:26:58","slug":"deerfield-provides-125-million-debt-financing-to-tris-pharma","status":"publish","type":"post","link":"https:\/\/www.trispharma.com\/deerfield-provides-125-million-debt-financing-to-tris-pharma\/","title":{"rendered":"Deerfield Provides $125 million Debt Financing to Tris Pharma"},"content":{"rendered":"
Published on October 04, 2018<\/p>\n
Deerfield provides growth capital financing to Tris Pharma<\/p>\n
New York, New York \u2013 October 4, 2018 \u2013 Deerfield announced today it provided $125 million to refinance existing debt and provide growth capital to Tris Pharma, Inc. \u00a0This financing allows Tris to expand its branded pharmaceutical portfolio with a particular focus on Attention Deficit Hyperactivity Disorder (ADHD), launch and promote new products and continue development of its drug development platform.<\/p>\n
In addition to the financing, Deerfield and Tris plan to enter into a product development agreement to leverage Tris\u2019 proprietary drug delivery technology.<\/p>\n
\u201cDeerfield has partnered with Tris to provide a solution to address all our capital needs in a manner that allows Tris to fully focus on rapidly growing our branded ADHD business and expanding our R&D commitment,\u201d stated Ketan Mehta, president and chief executive officer of Tris. \u201cAdditionally, by leveraging our drug delivery technology in partnership with Deerfield, we benefit from Deerfield\u2019s expertise and capabilities.\u201d<\/p>\n
\u201cThis financing provides a solid foundation upon which Tris can promote and launch existing and new products, and we look forward to its success.\u00a0 Furthermore, Deerfield is delighted to collaborate with Tris\u2019 strong management team as a long-term partner, and to develop new drugs that can be delivered through the company\u2019s proprietary technology\u201d stated Jim Flynn, Deerfield\u2019s managing partner.<\/p>\n
About Deerfield<\/strong><\/p>\n Deerfield is an investment management firm committed to advancing healthcare through investment, information and philanthropy.<\/p>\n For more information, please visit www.deerfield.com<\/a><\/span><\/p>\n Contacts<\/strong><\/p>\n Deerfield Management Company<\/p>\n Karen Heidelberger, 212-551-1600<\/p>\n